Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01183
|
|||||
Drug Name |
Etoricoxib
|
|||||
Synonyms |
5-Chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine; 5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine; 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine; 5CH; Algix; Algix (TN); Arcoxia; Arcoxia (TN); Etoricoxib (USAN/INN); Etoricoxib [USAN:INN:BAN]; Etoricoxibe; L-791456; L791456; MK 0663; MK 663; MK-0663; MK-663; Merck Sharp & Dohme brand of etoricoxib; Nucoxia; Tauxib; Tauxib (TN)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Therapeutic Class |
Antiinflammatory Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C18H15ClN2O2S
|
|||||
Canonical SMILES |
CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
|
|||||
InChI |
InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
|
|||||
InChIKey |
MNJVRJDLRVPLFE-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 202409-33-4
|
|||||
Pharmaceutical Properties | Molecular Weight | 358.8 | Topological Polar Surface Area | 68.3 | ||
Heavy Atom Count | 24 | Rotatable Bond Count | 3 | |||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 4 | |||
XLogP |
3.3
|
|||||
PubChem CID | ||||||
PubChem SID |
10240801
, 103169851
, 103853298
, 103965754
, 104418927
, 118048491
, 12015199
, 125536726
, 126645211
, 126671483
, 128620771
, 134338025
, 135079337
, 137001913
, 13883
, 142355996
, 144205759
, 14828179
, 160964864
, 162188900
, 163123240
, 163414197
, 163620860
, 163686187
, 163849037
, 164787972
, 170465621
, 171579232
, 17397801
, 175266728
, 175611945
, 176484244
, 177749312
, 178100245
, 26758000
, 29303851
, 46504505
, 49655565
, 50065687
, 57340488
, 58108264
, 6613371
, 76715678
, 79356674
, 7979618
, 85209827
, 92309001
, 99214846
, 99437360
, 99443637
|
|||||
TTD Drug ID |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.